Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline

By /

Vico Therapeutics B.V. announced a $60 million Series B financing.

Scroll to Top